Can Fite Biopharma

Can Fite Biopharma Assets per Share

The Total Assets per Share of Can Fite Biopharma (CANF.TA) as of Nov 9, 2026 is 13.25 USD. In the previous year, Total Assets per Share was 12.70 USD — a change of 4.34% (higher).

Assets per Share

13.25USD

YoY

4.34%

Last updated:

Total Assets per Share of Can Fite Biopharma is 2025 13.25 USD. Total Assets per Share of Can Fite Biopharma was 2024 12.70 USD. It decreases by 4.34% higher compared to the previous year.

The Can Fite Biopharma Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
11.07 USD
Jan 1, 2019
11.38 USD
Jan 1, 2020
13.26 USD
Jan 1, 2021
28.20 USD
Jan 1, 2022
12.93 USD
Jan 1, 2023
13.91 USD
Jan 1, 2024
12.70 USD
Jan 1, 2025
13.25 USD
The Can Fite Biopharma Assets per Share history
YEARAssets per ShareYoY
13.25USD+4.34%
12.70USD-8.70%
13.91USD+7.61%
12.93USD-54.16%
28.20USD+112.67%
13.26USD+16.50%
11.38USD+2.79%
11.07USD+1.53%
10.91USD-22.96%
14.16USD-42.24%
24.51USD+427.29%
4.65USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Can Fite Biopharma Stock analysis

What does Can Fite Biopharma do? Can-Fite Biopharma Ltd. is an Israeli company specializing in the development of drugs for inflammatory diseases and cancer. It was founded in 1994 by Prof. Pnina Fishman and is headquartered in Petach Tikva, Israel. The company initially focused on studying the function of adenosine receptors in central nervous system diseases, but later expanded to develop drugs for inflammatory diseases and cancer. Can-Fite went public in 2007 and has been able to finance its research projects through investors and partnerships. The company's business model revolves around developing an innovative portfolio of drugs for immune system disorders and cancer by targeting adenosine receptors. It aims to expand its drug pipeline to successfully treat a wide range of diseases. Can-Fite's drug pipeline is divided into different areas, including inflammatory diseases, cancer, and ophthalmology. The company has already brought several drugs to market or is in the clinical testing phase, including CF101 for rheumatoid arthritis and psoriasis, Namodenoson for liver cancer, and Piclidenoson for autoimmune diseases. Overall, Can-Fite Biopharma Ltd. is a promising company focused on developing innovative drugs for inflammatory diseases and cancer. Can Fite Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Can Fite Biopharma stock

Total Assets per Share of Can Fite Biopharma is 13.25 USD in 2025.

Total Assets per Share of Can Fite Biopharma changed from 12.70 USD to 13.25 USD, representing a 4.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Can Fite Biopharma since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Can Fite Biopharma

All Key Metrics — Can Fite Biopharma